Get the Stockscreener App
10.48
1.95%
0.20
After Hours:
10.48
Neuropace Inc stock is traded at $10.48, with a volume of 105.56K.
It is up +1.95% in the last 24 hours and up +6.29% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
See More
Previous Close:
$10.28
Open:
$10.33
24h Volume:
105.56K
Relative Volume:
0.57
Market Cap:
$346.69M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-8.252
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
-2.69%
1M Performance:
+6.29%
6M Performance:
+0.58%
1Y Performance:
+58.55%
1-Day Range:
$10.28
$10.66
1-Week Range:
$10.25
$11.25
52-Week Range:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.48 | 340.08M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
131.38 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.95 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.92 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.58 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
NeuroPace Inc. stock outlook for YEARMarket Growth Summary & Free High Accuracy Swing Entry Alerts - newser.com
Applying Elliott Wave Theory to NeuroPace Inc.July 2025 Breakouts & Real-Time Market Trend Scan - newser.com
How to integrate NeuroPace Inc. into portfolio analysis toolsJuly 2025 Market Mood & Verified Technical Trade Signals - newser.com
Will NeuroPace Inc. price bounce be sustainableJuly 2025 Movers & Safe Entry Point Identification - newser.com
Can NeuroPace Inc. stock sustain revenue growth2025 Price Targets & AI Forecast Swing Trade Picks - newser.com
Tools to assess NeuroPace Inc.’s risk profileTrade Ideas & Daily Profit Maximizing Tips - newser.com
NeuroPace, Inc. (NASDAQ:NPCE) Receives $16.60 Average Price Target from Analysts - Defense World
NeuroPace's (NPCE) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Automated trading signals detected on NeuroPace Inc.Trade Analysis Summary & Free Technical Pattern Based Buy Signals - newser.com
What momentum shifts mean for NeuroPace Inc.2025 Market Overview & Community Consensus Stock Picks - newser.com
NeuroPace Inc. recovery potential after sell offInsider Selling & Verified Swing Trading Watchlist - newser.com
What analysts say about NeuroPace Inc stockEx-Dividend Date Alerts & Stay One Step Ahead of Risk Events - earlytimes.in
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
NeuroPace Inc Stock Analysis and ForecastDouble Top/Bottom Patterns & Affordable Portfolio Growth - earlytimes.in
Using economic indicators to assess NeuroPace Inc. potentialJuly 2025 Setups & AI Powered Market Entry Ideas - newser.com
HighMark Wealth Management LLC Purchases 60,000 Shares of NeuroPace, Inc. $NPCE - MarketBeat
Neuropace chief medical officer Morrell sells $48,032 in stock - MSN
What drives NeuroPace Inc stock priceTrading Volume Surges & Get Mentorship from Elite Traders - earlytimes.in
Epilepsy Treatment Devices Market Hits New High | Medtronic, NeuroPace, LivaNova, Boston Scientific - newstrail.com
Why NeuroPace Inc. stock is trending among retail tradersJuly 2025 Final Week & Growth Focused Stock Pick Reports - The British Mountaineering Council
Palumbo Wealth Management LLC Grows Stake in NeuroPace, Inc. $NPCE - MarketBeat
Why NeuroPace Inc. is moving todayGap Down & Comprehensive Market Scan Reports - newser.com
Will NeuroPace Inc. outperform the marketWeekly Profit Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Is NeuroPace Inc. building a consolidation baseInsider Selling & Short-Term Swing Trade Alerts - newser.com
NeuroPace Inc. stock prediction for this weekPortfolio Gains Report & Safe Entry Zone Identification - newser.com
Forecasting NeuroPace Inc. price range with options data2025 Short Interest & Target Return Focused Stock Picks - newser.com
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 25% Price Jump - simplywall.st
Using Vision Transformers for Electrographic Seizure Classification to Aid Physician Review of Intracranial Electroencephalography Recordings - Frontiers
Using vision transformers for electrographic seizure classification to aid physician review of intracranial electroencephalography recordings - Frontiers
How to recover losses in NeuroPace Inc. stock2025 Top Decliners & Short-Term Swing Trade Alerts - newser.com
NeuroPace, Inc. (NASDAQ:NPCE) Receives $16.60 Consensus Target Price from Analysts - MarketBeat
NeuroPace raises FY25 revenue view to $94M-$98M, consensus $94.78M - MSN
Aug Sectors: What makes NeuroPace Inc stock attractive today2025 Key Lessons & Fast Momentum Entry Tips - خودرو بانک
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuropace Inc Stock (NPCE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
0.01%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):